Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
July 13, 2016
- Despite Brexit, Importance of UK “Will Remain Unchanged”: Dr Suematsu of AMED
July 12, 2016
- AMED Aims to Facilitate Drug Makers’ Access to Knowledge at Research Institutions: President
July 12, 2016
- PMDA Inks Comprehensive Collaboration Accord with NCNP
July 12, 2016
- MHLW to Put Expensive Drug Issue Up for Chuikyo Discussion ASAP: Medical Economics Division Chief
July 11, 2016
- “New Rules” for Expensive Drugs Could Impact Business Models: Health Insurance Bureau Chief
July 8, 2016
- Number of Academia-Originated Drugs Highest in Oncology: AMED Survey
July 7, 2016
- Imusera/Gilenya Don’t Delay Disability Progression in Primary Progressive MS, MHLW Orders Label Revisions
July 6, 2016
- MHLW OKs Sanofi’s PCSK9 Inhibitor, Other Drugs
July 5, 2016
- MHLW to Issue “Blue Book” on Quality of Generics by March-End
July 1, 2016
- It’s Now Up to UK Govt to Decide on Future Action after Brexit Vote: EMA Spokesperson
June 30, 2016
- MHLW Begins Interim Review of 10-Year Strategy on Hepatitis Research
June 29, 2016
- MHLW Restresses Risk of HBV Reactivation for 8 Hep C Drugs
June 29, 2016
- Key Govt Panel Meets to Discuss Brexit’s Impact on Industries
June 29, 2016
- AMED Sets Up First Overseas Outpost in Singapore
June 28, 2016
- MHLW Vows to Forge Ties with UK Counterpart in Post-Brexit Regulations
June 27, 2016
- JEC Rengo Petitions MHLW to Eliminate “Huge-Seller” Repricing in Its Policy Proposal
June 27, 2016
- Panel to Discuss Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose for Public Immunization Program
June 24, 2016
- Registration System for Prevention of Dementia to Begin Operation; Will Provide Info on Clinical Research, Trials
June 24, 2016
- MHLW Official Vows to Swiftly Present Proposal on “Optimal Use of Innovative Drugs”: Chuikyo
June 23, 2016
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…